BioNTech CEO Sahin Ugur Sells 61,000 Shares

What Happened
Sahin Ugur, CEO of BioNTech SE (BNTX), sold a total of 61,000 ordinary shares in two open-market transactions: 27,000 shares on 2026-09-25 at $98.69 ($2,664,581) and 34,000 shares on 2026-09-28 at $98.47 ($3,347,919), for aggregate proceeds of $6,012,500. These were sales (not purchases) and were reported on a Form 4 filed 2026-09-28.

Key Details

• Transaction dates & prices: 2026-09-25 — 27,000 shares @ $98.69; 2026-09-28 — 34,000 shares @ $98.47.
• Total proceeds: $6,012,500.
• Shares owned after transaction: Not specified in the provided Form 4 excerpt. The filing indicates the ordinary shares are held by Medine GmbH, of which Mr. Sahin is the sole shareholder; 106,721 of the shares noted are held for the benefit of an individual under a trust arrangement (see footnote).
• Notable footnote: Medine GmbH holds the ordinary shares; the reporting person is sole shareholder and may be deemed to beneficially own those shares. Medine exercises voting power but not dispositive power over 106,721 trust-held shares.
• Trading plan: The sales were effected pursuant to a Rule 10b5-1 trading plan established by Mr. Sahin on June 3, 2026 (noticed in the Form 4 remarks).
• Filing timeliness: Form 4 filed on 2026-09-28 reporting sales on 9/25 and 9/28; the filing does not indicate lateness.

Context
Rule 10b5-1 plans allow insiders to pre-schedule trades and are commonly used to avoid questions about trading on material nonpublic information; sales under such plans are often routine liquidity transactions and do not by themselves indicate a change in company outlook. The shares involved appear to be held through Medine GmbH, so the reported sales reflect the reporting person's beneficial interest via that entity.